FFO
LFCR icon

Fortitude Family Office’s Lifecore Biomedical LFCR Stock Holding History

Fortitude Family Office’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-265
Closed -$1.87K – 2085
2025
Q1 		$1.87K Hold
265
– – ﹤0.01% 931
2024
Q4 		$1.97K Hold
265
– – ﹤0.01% 1037
2024
Q3 		$1.31K Hold
265
– – ﹤0.01% 1067
2024
Q2 		$1.36K Hold
265
– – ﹤0.01% 846
2024
Q1 		$1.41K Hold
265
– – ﹤0.01% 873
2023
Q4 		$1.64K Buy
+265
New +$1.84K ﹤0.01% 895

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GC
Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return

Fortitude Family Office's LFCR Position: Q2 2025 in Review

Fortitude Family Office sold out of Lifecore Biomedical (LFCR) in Q2 2025, closing a stake of 265 shares — an estimated $1.87K sold.

Fortitude Family Office first reported a position in LFCR in Q4 2023 and held it in 6 quarters. The position peaked at $1.97K in Q4 2024. 86 funds tracked by Wall St. Rank hold LFCR as of Q2 2025.

  • Fortitude Family Office reported no remaining Lifecore Biomedical position as of Q2 2025 after selling out during the quarter.
  • Fortitude Family Office sold 265 Lifecore Biomedical shares in Q2 2025, an estimated $1.87K.
  • Fortitude Family Office first reported a position in Lifecore Biomedical in Q4 2023 and held it in 6 quarters.
  • Fortitude Family Office's Lifecore Biomedical position peaked at $1.97K in Q4 2024.
  • 86 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2025.

Based on Fortitude Family Office's 13F filing for Q2 2025, filed 15 Jul 2025.